Cigarette smoke-induced oxidative stress leads to dyslipidemia and systemic inflammation. Morinda citrifolia (noni) fruit juice has been found previously to
have a significant antioxidant activity. One hundred thirty-two adult heavy smokers completed a randomized, double blind, placebo-controlled clinical trial designed to investigate the effect of noni juice on serum cholesterol, triglyceride, low density lipoprotein cholesterol (LDL), high density lipoprotein cholesterol (HDL), high-sensitivity C-reactive protein (hs-CRP), and homocysteine. Volunteers drank noni juice or a fruit juice placebo daily for one month. Drinking 29.5 mL to 188 mL of noni juice per day significantly reduced cholesterol levels, triglycerides, and hs-CRP. Decreases in LDL and homocysteine, as well increases in HDL, were also observed among noni juice drinkers. The placebo, which was devoid of iridoid glycosides, did not significantly influence blood lipid profiles or hs-CRP. Noni juice was able to mitigate cigarette smoke-induced dyslipidemia, an activity associated with the presence of iridoids.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.
"The noni juice showed hypolipidemic and antioxidative effects on high-fat/ cholesterol-dietary hamsters. It is proposed that the antioxidative  and anti-inflammatory properties   of noni may provide a protective effect against neuronal damage caused by hydrocephalus. Image analysis showed that the staining density of microtubuleassociated protein-2 following noni administration was greater than in hydrocephalic rabbits, indicating that noni reduced loss of microtubule-associated protein-2 immunostaining density. "
[Show abstract][Hide abstract]ABSTRACT: This study was designed to evaluate the neuroprotective effects of Morinda citrifolia L. (Rubiaceae), commonly known as noni, and memantine (a N-methy-D-aspartate receptor inhibitor) on hydrocephalus-induced neurodegenerative disorders. Kaolin was injected into the cistern magna of male adult New Zealand rabbits to establish a hydrocephalus animal model. Memantine (20 mg/kg, intraperitoneally; memantine-treated group) or noni (5 mL/kg, intragastrically; noni-treated group) was administered daily for 2 weeks. Microtubule-associated protein-2 and caspase-3 immunohistochemistry were performed to detect neuronal degeneration and apoptosis in the periventricular tissue of the fourth ventricle of rabbits. Microtubule-associated protein-2 staining density was significantly decreased in the hydrocephalic group, while the staining density was significantly increased in the memantine- and noni-treated groups, especially in the noni-treated group. Noni treatment decreased the number of caspase-3-positive cells in rabbits with hydrocephalus, while memantine had no effect. These findings suggest that noni exhibits more obvious inhibitory effects on hydrocephalus-induced neurodegenerative disorders than memantine in periventricular tissue of the fourth ventricle.
Full-text · Article · Mar 2013 · Neural Regeneration Research
[Show abstract][Hide abstract]ABSTRACT: Aim:
In this work we evaluated the possibility for dietary supplement COLOSTRO NONI to be used as preventive and therapeutic agent in various diseases characterized by altered intestinal homeostasis with changes in the composition of the microbiota, alteration of the morphology and functionality, and also inflammation of the epithelium.
Cellular activity of COLOSTRO NONI has been tested in an in vitro model of intestinal epithelium based on Caco-2 cell line. We tested the ability of COLOSTRO NONI to stimulate cellular turnover evaluating cell growth rate with WST-1 proliferation assay. We also tested the ability of COLOSTRO NONI to increase the gene expression of Interleukin-8 (IL-8) with a Real Time PCR assay. IL-8 is a fundamental chemotactic factor involved in inflammatory phenomena and in the control of tissue homeostasis.
COLOSTRO NONI is able to stimulate cell turnover in the proposed in vitro model and demonstrates active in increasing the gene expression of IL-8. Both aspects observed are fundamental for the establishment of mechanisms to repair tissue damage.
Obtained results indicate that COLOSTRO NONI could find clinical application in treatment of gastrointestinal disorders characterized by impairment of proper intestinal permeability, in inflammatory bowel diseases, in dysenteric diseases, in gastritis and in forms of pathological alteration of the mucous layer as celiac disease and gluten sensitivity.
No preview · Article · Mar 2014 · Minerva gastroenterologica e dietologica
[Show abstract][Hide abstract]ABSTRACT: Purpose: To investigate the reducing effect of Morinda citrifolia capsules (MCC) on total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-C) in hypercholesterolemia patients. Methods: This study was a randomized double-blind placebo-controlled clinical trial, with 60 subjects placed in two groups, viz, experimental (MCC group) and placebo (P group). The first group received two capsules of MCC (each capsule contains 500 mg extract) while the second group received two capsules of placebo (comprised of 500 mg fillers) 3 times daily, for 14 days for both groups. Overnight fasting cubiti venous blood (3 mL) was taken from each subject each time measurements were carried out. TC and LDL-C were measured by spectrophotometric assay using an automated analyzer. Results: The results show that there was significant decrease in TC and LDL-C on day 14, compared to control (P group). Reduction in TC and LDL-C was 13.8 and 15.5 %, respectively. Decrease in TC and LDL-C levels was influenced by factors, such as age, BMI, exercise, diet, and smoking habits. In MCC group, the capsules significantly decreased TC levels (p < 0.05). Conclusion: The results suggest that 1 g MCC, given orally thrice daily, significantly reduces TC and LDL-C levels in patients with hypercholesterolemia.